Aim: To evaluate the diagnostic performance of serumAFUfor early stage hepatocellular carcinoma (HCC). Methods: Concentration of AFU and AFP were measured in 512 patients. The performance was compared for AFU and AFP alone or in combination. Results: The area under the curve (AUC) for AFU was 0.68, with a sensitivity of 56.1% and specificity of 69.2% at the cut-off value of 24U/l; whereasthe AUC for AFP was 0.83, with a sensitivity of 58.2% and specificity of 85.2% at cut-off value of 20ng/ml. The AUC of AFU alone or the combination with AFP were lower than that of AFP alone. Conclusion: AFU is a suboptimal biomarker for early detection of HCC.
基金：
National Natural Science Foundation of China [81472284, 81672699]
第一作者单位：[1]Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Surg, Shanghai, Peoples R China
通讯作者：
推荐引用方式(GB/T 7714)：
Xing Hao,Qiu Haibo,Ding Xuemei,et al.Clinical performance of α-L-fucosidase for early detection of hepatocellular carcinoma[J].BIOMARKERS IN MEDICINE.2019,13(7):545-556.doi:10.2217/bmm-2018-0414.
APA：
Xing, Hao,Qiu, Haibo,Ding, Xuemei,Han, Jun,Li, Zhenli...&Yang, Tian.(2019).Clinical performance of α-L-fucosidase for early detection of hepatocellular carcinoma.BIOMARKERS IN MEDICINE,13,(7)
MLA：
Xing, Hao,et al."Clinical performance of α-L-fucosidase for early detection of hepatocellular carcinoma".BIOMARKERS IN MEDICINE 13..7(2019):545-556
